Radiation therapy firm North American Scientific (NAS) has received Food and Drug Administration clearance to market its Prospera SurTrak line of brachytherapy products for the treatment of prostate cancer.
The new family of products includes the SurTrak preplugged needle with a synthetic, microangled insert for improved seed delivery and placement, the company said. The SurTrak strand, used in conjunction with the needle, is bioresorbable and designed to hold the seeds at predetermined distances.
The new SurTrak needle will also be available preloaded with seeds and spacers per the physician's prescription, according to the Chatsworth, CA-based firm.
By AuntMinnie.com staff writers
February 7, 2006
Related Reading
NAS fiscal 2005 results impacted by Nomos purchase, January 10, 2006
NAS readies serial tomotherapy package, October 10, 2005
NAS gets China OK for Peacock, September 21, 2005
NAS trims losses in Q3, September 6, 2005
NAS, Oncura sign palladium-103 deal, July 21, 2005
Copyright © 2006 AuntMinnie.com
